Sponsored by
This is an exciting new treatment. The Musella Foundation helped fund part of it. OS2966 is a brand new class of treatment, which targets CD29/B1 integrins which are highly upregulated in Glioblastomas and have been shown to drive tumor progression and invasion as well as participate in the resistance pathways.